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Background: Survival data from hospital-based or clinical trial studies of patients with chronic heart failure (CHF) do not represent survival
in community-based settings.
Aims: To determine the incidence of CHF and the associated long-term survival in a community-based sample aged 57 years and to assess
the mortality risk associated with sex and age.
Methods: This study was part of the Groningen Longitudinal Aging Study.
Results: Annual incidence of CHF per 1000 ranged from 2.5 in middle aged adults (57–60 years) up to 22.4 in older females (80 years)
and 28.2 in older males (80 years). The 1, 2, 5 and 7-year survival rates were 74%, 65%, 45%, 32% for patients with CHF, compared to
97%, 94%, 80% and 70% in a matched reference group without CHF. Higher age (76 years) was a risk factor for mortality (OR=2.1) and
male sex was a risk factor in those aged 75 years (OR=1.9) but not for older patients.
Conclusion: Long-term survival rates for patients with CHF in the community were worse than the known survival rates from clinical trials.
There is a need for studies describing the care of patients with CHF in the community, including the type of care, the provider, the quality of
care and the outcome.
D 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.Keywords: Heart failure; Survival; Incidence; Epidemiology; Elderly; Sex1. Introduction
Chronic heart failure (CHF) is a common and growing
health problem especially among the elderly. Despite
advances in therapeutic interventions, CHF has a poor
prognosis both in terms of morbidity and mortality.
Estimates of mortality among CHF patients are available
from various sources, including clinical trials, hospital-
based studies and community-based samples. Data on long-
term mortality are often lacking in clinical trials. An1388-9842/$ - see front matter D 2005 European Society of Cardiology. Publishe
doi:10.1016/j.ejheart.2005.04.012
* Corresponding author. Tel.: +31 50 3633208; fax: +31 50 3632406.
E-mail address: evanjaarsveld@gmail.com (C.H.M. van Jaarsveld).exception is the COMET trial which reports a 5-year
mortality rate of 35%–41% [1]. Hospital-based studies
include patients who are selected during hospitalization for
CHF or from hospital outpatient settings. Such hospital-
based studies, report 5-year mortality rates of 48% [2] and
77% [3] compared to 45%–67% for community-based
samples [4–6]. A recent large community-based study in
the UK reported 3-year mortality rates of 67% in male and
60% in female patients with CHF [7]. Clearly, estimates of
long-term mortality differ according to the source of the
data. Moreover, data from the 1980s may not be represen-
tative of the current situation, since new therapies for CHF,
such as angiotensin-converting-enzyme-inhibitors and beta-t Failure 8 (2006) 23 – 30d by Elsevier B.V. All rights reserved.
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trials on therapeutic interventions among CHF patients
show that these advances in therapy increase survival [3,8–
11]. Recent large clinical trials suggest that the annual
mortality rate among patients with CHF is approximately
10% [1,12–14]. It is, however, questionable whether these
trends in CHF survival seen in clinical trials are applicable
to patients in the community [15–17].
Most patients with CHF are treated in the community, but
the evidence base for their treatment is largely derived from
clinical trials and observational studies of hospital-based
patients. A number of variables distinguish patients with
CHF who are recruited for clinical trials from those in
hospital or community settings. Patients in clinical trials are
more likely to be male, more likely to have their diagnosis
corroborated by structured assessment and formalized
criteria and less likely to have medical comorbidities that
may contribute directly to mortality and complicate the
management of CHF [18]. In addition, patients in the
community are about a decade older than patients in clinical
trials [19]. Estimates of mortality in hospital-based studies
are also from selected populations, since they select patients
from consecutive hospital admissions or hospital outpatient
settings, who are more likely to be treated by cardiologists
rather than solely relying on primary care physicians. These
differences may limit the validity of comparisons between
these three types of CHF patient.
The objective of this study was therefore to determine the
incidence (in age and sex strata) and long-term survival of
CHF in a community based sample of subjects aged 57
years; and to assess the mortality risk associated with sex
and age. In addition, survival rates will be compared to sex–
age matched subjects without CHF.2. Methods
This study was part of the Groningen Longitudinal Aging
Study (GLAS). In this community-based sample of subjects
aged 57 years or older, incident cases of CHF were
identified by general practitioners between 1993 and 1998
and survival data were collected up to 2001.
2.1. Groningen longitudinal aging study
A detailed description of data collection has been
published elsewhere [20–23]. Briefly, the source population
was late middle-aged and older adults, living independently
or in old people’s homes in the northern part of the
Netherlands. The study population comprised 8723 subjects
aged 57 years or older on January 1, 1993, who were
registered as patients with the 27 general practitioners
participating in the Morbidity Registration Network Gro-
ningen. In the Netherlands, nearly 100% of non-institution-
alized older adults are registered with a general
practitioner’s practice. A total of 1937 subjects refused toparticipate (22%). Of the remaining 6786, 1277 declined to
participate when contacted by the research team, and 152
had died or left the practice by the time contact was
initiated. Another 78 subjects were excluded because of
severe cognitive impairment at baseline (Mini-Mental State
Examination Score of 16 or lower). Useful baseline data
were available for 5279 subjects (62%; 5279 / (8723 -152))
(see Appendix). The GLAS baseline assessment was carried
out in 1993 and consisted of an interview and a question-
naire sent by mail. Non-response was associated with age
(34% non-response for subjects aged 57 to 69, 42% for
subjects aged 70 to 84, and 67% for subjects 85 years or
older) and with sex (37% non-response for men, 41% for
women). The characteristics of the GLAS baseline sample
were assessed by comparisons on four clusters of physician-
registered morbidity. There was a higher proportion of
patients with malignant neoplasm among non-responders,
but no significant differences were found for ischemic heart
disease and CHF, chronic respiratory diseases and chronic
diseases of the locomotor apparatus [20,21]. The GLAS
baseline study and its follow-up studies were approved by
the local medical ethics committee and all participants gave
written consent to participate in the study.
2.2. New patients with CHF
New patients with CHF were recruited from the 5279
GLAS baseline participants through the 27 general practi-
tioners participating in the Morbidity Registration Network
Groningen. From the baseline wave in 1993 until January 1,
1998, these physicians passed on the names of all patients
with a new diagnosis of CHF according to the criteria of the
International Classification of Primary Care (ICPC) [24].
Subjects who were diagnosed with CHF before 1993 were
excluded from the cohort. CHF was diagnosed if three of the
following five symptoms were present: (a) dependant
oedema, (b) raised jugular venous pressure or hepatomegaly
in the absence of liver disease, (c) signs of pulmonary
congestion or pleural effusion, (d) enlarged heart or (e)
dyspnoea in the absence of pulmonary disease (code K77 of
the ICPC). During the enrolment period (1993–1998), 293
patients with a first diagnosis of CHF after baseline were
recruited. The mean time interval between the baseline
interview and the diagnosis of CHF was 28 months and
ranged from 15 days to 5 years.
2.3. Subjects without CHF
All 4986 GLAS participants who did not have a new
diagnosis of CHF (between 1993–1998) were included in
the study to calculate the incidence rates of CHF for each
sex–age stratum. In addition, reference subjects (matched
according to sex and age T1 years) were selected from these
4986 subjects without CHF. According to these rules, two
matched reference subjects were successfully identified for




























male 2,5 6,4 20,0 28,2
female 2,5 4,1 15,4 22,4
57-60 61-69 70-79 80+
Fig. 1. Incidence rates of CHF among GLAS subjects by sex and age.
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had other chronic diseases. The purpose of this matched
reference group was to illustrate the mortality risk in a
sample without CHF with a comparable sex and age
distribution.
2.4. Mortality
Survival status was checked for all patients and reference
subjects at approximately 8 years after the baseline assess-
ment in 1993 (i.e. June 1st, 2001). Data on all-cause
mortality were collected using municipal registrations.
2.5. Baseline characteristics
Sex, age, educational level, marital status, and comorbid-
ity were assessed at the baseline interview in 1993. Pre-
valence of (other) chronic diseases was assessed using a
checklist, comprising 19 chronic medical conditions: asthma
or chronic bronchitis, pulmonary emphysema, heart con-
dition, hypertension, (consequences of) stroke, leg ulcer,
stomach ulcer, liver disorder or gallstones, kidney disease,
prostate problem, diabetes mellitus, thyroid gland disorder,
back problems for at least 3 months or slipped disc, joint
conditions or arthritis, migraine or chronic headache, serious
dermatological disorders, cancer, multiple sclerosis, Parkin-
son’s disease or epilepsy. Participants were asked whether
they suffered from one or more of these conditions in the 12
months prior to the interview. In order to reduce report-bias,
only those conditions that required a GP or specialist consul-
tation and/or prescription of medicine were counted. This
procedure was similar to procedures used by the Netherlands
Central Office of Statistics in periodic health surveys [25].
2.6. Analyses
Incidence rates for CHF according to sex and age strata
were calculated by dividing the total number of incident
CHF cases in each stratum by the total number at risk (i.e.
incidence in 5 years (1993–1998)). Annual incidence rates
were calculated by dividing these 5-year incidence rates
by 5.
Baseline characteristics of CHF patients (n =293) and
GLAS subjects who did not develop CHF (n =4986) were
compared using t-test and Chi-square tests. A P value of
<0.05 was considered significant. Kaplan–Meier survival
tables and curves were calculated for CHF patients and sex–
age matched reference subjects. Survival rates were
presented for patients at 1 month, 6 months, 1 year, 2, 3,
4, 5, 6 and 7 years after diagnosis. For reference subjects the
survival rates at the same intervals since the baseline
assessment in 1993 were presented. Kaplan–Meier survival
tables were used to estimate the survival rates and 95%
Confidence Intervals (95% C.I.) at several intervals.
Survival curves for patients and reference subjects were
presented according to sex and age (subjects aged 75years versus subjects aged 76 years). A cut off score of 75
years was used to create two groups of equal size.
In addition, COX-proportional-hazard analyses were
performed to calculate the hazard rates associated with
CHF, sex and age. Among CHF patients, hazard rates (Odds
Ratios) for mortality were presented for males versus
females and for subjects aged 75 years versus subjects
aged 76 years. Analyses were performed using SPSS for
Windows version 12.3. Results
3.1. Incidence of CHF in GLAS study
From the 5279 subjects who participated in the GLAS
baseline assessment in 1993, a total of 293 subjects
developed CHF in a 5 year period (1993 and 1998). Annual
incidence rates of CHF among the GLAS subjects, accord-
ing to sex and age are presented in Fig. 1. CHF incidence
increased with age, and was somewhat higher among males
than females.
3.2. Characteristics of patients developing CHF and
subjects without CHF
Characteristics of patients developing CHF and all other
GLAS subjects are presented in Table 1. Compared to
GLAS subjects who did not develop CHF between 1993
and 1998, the 293 CHF patients were significantly older
(mean age at baseline 75.5 years), were less well educated
and more often lived without a partner (43%). In addition,
CHF patients had more chronic conditions at baseline
(mean=1.7) compared to GLAS subjects who did not
develop CHF, and were significantly more likely to suffer
from hypertension (29%), cardiac disease with no further
detail (40%), diabetes (14%), asthma or chronic bronchitis
(18%) and pulmonary emphysema (9%). The percentage of
patients suffering the consequences of stroke and other
chronic conditions (data not shown) and the percentage of
Table 1
Baseline characteristics of GLAS subjects who developed CHF and those














Mean (SD) 75.5 (7.4) 69.2 (7.9) <0.001
Range 58–96 57–99
Sex
% Females 52 56 0.157
Marital status
% Without partner 43 32 <0.001
Educational level
% Low 43 35 0.017
% Medium 49 54
% High 8 11
No. of chronic diseases
Mean (SD) 1.7 (1.4) 1.1 (1.2) <0.001
Range 0–7 0–10
% Subjects with no.
of chronic diseases
None 20 36 <0.001
1 33 33
2 22 18
3 or more 25 13
% Hypertension 29 22 0.009
% Cardiac disease with
no further detail
40 19 <0.001
% (Consequences of) stroke 4 2 0.128
% Diabetes Mellitus 14 7 <0.001
% Asthma or chronic bronchitis 18 9 <0.001
% Pulmonary emphysema 9 3 <0.001
C.H.M. van Jaarsveld et al. / The European Journal of Heart Failure 8 (2006) 23–3026females did not differ significantly between CHF patients
and the GLAS subjects who did not develop CHF between
1993 and 1998.
3.3. Survival rates among patients and sex–age matched
reference subjects
The survival rates among CHF patients and sex–age
matched reference subjects are presented in Table 2. For
CHF cases, survival since diagnosis is presented. PatientsTable 2
Survival rates among CHF patients and sex–age matched reference subjects
Survival rates at time intervals in percent (95% Co
1 month 6 months 1-year 2-year
CHF patients(n =293) 90(87–93) 83(78–87) 74(69–79) 65(59
Reference subjects(n =586) 100- 99(98–100) 97(96–98) 94(92
* For CHF patients the interval represents the time since diagnosis. Patients were d
Therefore, follow-up since diagnosis is complete up to 3 years; and 4-, 5-, 6- an
respectively.
For reference subjects the time intervals are since the baseline assessment, which w
7 years for all reference subjects.were diagnosed between 1993 and 1998, and survival status
was evaluated in 2001. Consequently, a minimum follow-up
since diagnosis of 3 years was available for all patients,
while a 7-year follow-up was available for 66% of patients.
For the reference subjects, the survival rates are presented
since the baseline assessment, which was performed in 1993
for all subjects. Therefore, follow-up is complete up to 7
years for all reference subjects. Among CHF patients, 74%
survived the first year, in other words 26% of patients died
within the first year following diagnosis. Subsequent annual
mortality rates among survivors were 12%, 14%, 9%, 11%,
14% and 18%, respectively, in the second to seventh years.
At 7-year follow-up, survival among CHF patients was
32%, compared to 70% among sex–age matched reference
subjects. Survival among patients with CHF was markedly
decreased compared to the sex–age matched reference
group without CHF. Compared to sex–age matched
reference subjects, CHF was associated with a 3.7 fold
increased mortality risk (Cox regression analyses: Odds
Ratio=3.7, 95% C.I.: 2.97–4.56).
3.4. Mortality risks associated with sex and age
The Kaplan–Meier survival curves for patients and sex–
age matched reference subjects are presented in Fig. 2A and
B. Results are presented for patients and matched reference
subjects aged 75 years and those aged 76 years or older
separately. Fig. 2A shows that among those aged 75 years or
less, both male patients and male reference subjects had
worse survival compared to their female counterparts.
Female patients aged 75 years (line C) had significantly
better survival compared to male patients aged 75 years
(line D). Fig. 2B shows that in the older age strata (76
years), male reference subjects had worse survival than
female reference subjects, but no significant difference was
observed between male and female CHF patients among
these older patients. The mean survival times in these strata
are presented below Fig. 2A and B and ranged from 71
months in female CHF patients aged 75 years to as little
as 40 months in male CHF patients aged 76 years.
Cox regression analyses were performed to quantify the
mortality risks associated with sex and age. Table 3 shows
that male sex was associated with a 1.9 (95% C.I: 1.16–3.11)nfidence Interval)*
3-year 4-year 5-year 6-year 7-year
–70) 56(51–62) 51(45–56) 45(39–51) 39(33–45) 32(25–39)
–96) 90(88–93) 86(83–89) 80(77–83) 74(70–78) 70(66–74)
iagnosed between 1993 and 1998, and survival status was evaluated in 2001.
d 7-year follow-up is available for 96%, 84%, 72%, and 66% of patients,
as performed in 1993 for all subjects. Therefore, follow-up is complete up to
Legend
Line Strata n Survival time in months 
Mean  (95% C.I.) 
A Female references aged ≥ 76 yr 170 83    (79-87) 
B Male references   aged ≥ 76 yr 120 73    (67-79) 
C Female patients   aged ≥ 76 yr 85 42    (34-49) 
D Male patients   aged ≥ 76 yr 60 40    (31-49) 
0 1 2 3 4 5 6 7 8























Line Strata n Survival time in months 
Mean  (95% C.I.) 
A Female references aged ≤ 75 yr 136 96    (94-99) 
B Male references   aged ≤ 75 yr 160 86    (82-90) 
C Female patients   aged ≤ 75 yr 68 71    (62-80) 
D Male patients   aged ≤ 75 yr 80 54    (45-62) 
0 1 2 3 4 5 6 7 8






















Fig. 2. Kaplan Meier survival curves for CHF patients since diagnosis and for sex–age matched reference subjects since baseline in those aged 75 years (A)
and those aged 76 years (B).
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75 years, while male sex was not significantly related to an
increased mortality risk among older patients. Patients with
higher age (76 years) had a significant increased mortality
risk compared to younger subjects, both among males
(OR=2.8) and females (OR=1.6).4. Discussion
This study reports the incidence and long-term survival
rates for patients with chronic heart failure (CHF) in a
community-based sample. The incidence of CHF clearly
increases with age and is somewhat higher among males,
which is in line with results from other epidemiological
studies [26,27]. Long-term survival rates among CHFTable 3
Cox regression models for mortality among CHF patients showing Odds
Ratios for sex and age
Characteristics of CHF patients (n =293) Mortality Risk
OR (95% C.I.)a P value
Sex [0=female, 1=male] All ages 1.4 (1.01–1.84) 0.041
Age75 years 1.9 (1.16–3.11) 0.011
Age76 years 1.1 (0.76–1.61) 0.551
Age [0=age75 years,
1=age76 years]
All sexes 2.1 (1.51–2.78) <0.001
Females 1.6 (1.06–2.42) 0.027
Males 2.8 (1.73–4.46) <0.001
a OR=Odds ratio, C.I.=Confidence interval of odds ratio.patients were low. From a comparison with GLAS subjects
who did not develop CHF between 1993–1998, it became
clear that the average CHF patient is characterized by older
age and having other chronic conditions, typically hyper-
tension, diabetes mellitus or lung diseases. Clearly these
characteristics contribute to the high mortality rates found in
this study. Mortality rates which are derived from clinical
trials suggest that the annual mortality rate among CHF
patients is about 10% [1,12–14], however our study shows
that mortality among CHF patients in the community is
much higher, especially in the first year after diagnosis.
A number of factors are likely to contribute to the higher
mortality rates observed in our community-based sample
compared to mortality rates in clinical trials. The overall
CHF population is older and has a higher comorbidity rate
than populations in clinical trials [19]. Studies of CHF in the
community generally describe prognosis from the onset of
CHF. It is clear that many patients who develop CHF
succumb rapidly to their condition and die within 1 to 6
months. The prognosis of patients with CHF who survive
beyond these first few months in the community, is possibly
more similar to that in clinical trials. However, if we focus on
patients who survive the first 6 months (i.e. 83% of the
original sample of patients), annual mortality rates among
survivors still exceed 10%. Furthermore, the effectiveness of
medical management is probably lower in a community
based population than in patients managed by clinical trial
investigators. Beyond potential differences in drug efficacy,
C.H.M. van Jaarsveld et al. / The European Journal of Heart Failure 8 (2006) 23–3028proven treatments are generally underused in the community
[28]. To date Ftypical_ CHF patients have largely been
excluded from clinical trials. This needs to change if the
prognosis of CHF patients in the general population is to be
improved [19].
Advances in therapeutic interventions for CHF have been
shown to increase survival in hospital-based studies [3,8,9].
Evidence that the prognosis of CHF in the general population
has improved over the past 50 years was found in the
Framingham Heart Study and in other surveys [5,29]. In
contrast, prognosis did not improve between 1981 and 1991
in the Rochester Epidemiology Project [6]. The continued
gap between outcome advances observed in clinical trials
versus the general community is disappointing. The fact that
in both primary and secondary care the therapeutic manage-
ment of CHF does not reflect current scientific evidence and
is still far from optimal may contribute to the lower survival
rates for CHF in the community [28].
A limitation of our study is that for case finding, this study
depended on the diagnosis and clinical judgments of general
practitioners, without confirming the diagnosis. Therefore,
milder, unconfirmed cases of CHF are also included. On the
other hand, milder cases may have been underrepresented in
our study, since subjects with minor symptoms may wait
before contacting their general practitioner. However, the
incidence rates for CHF in this community-based cohort are
comparable with rates found in the Framingham Heart Study
[26]. Moreover, we were interested in survival of patients
with (suspected) CHF according to the general practitioner.
Most subjects with CHF remain in the care of primary
physicians and therefore studying the outcome of patients
identified by general practitioners as having CHF is
important. The advantages of our study relate to the fact
that it is a population-based study and included elderly
participants. In the Netherlands, nearly 100% of non-
institutionalized adults are registered with a general practi-
tioner’s practice and the general practitioner must be
contacted before obtaining specialized medical care. Con-
sequently, all morbidity is registered by general practitioners,
which makes our sample more representative of incident
patients with CHF. In addition, we were able to collect
information on vital status (including date of death) of all
participants using municipal registrations.
The survival rates found in this community-based cohort
of middle aged and older patients corresponds to rates found
in large American studies, such as the Framingham Heart
Study (1990–1999 cohort) [5] and the Rochester Epide-
miological Project (1991 cohort) [6]. The slight differences
between reported survival rates can be traced to CHF
definition or study design. A population-based study in the
UK reports a lower 1-year survival rate (62%) compared to
the 74% in our study, which can be explained by the fact
that diagnosis was confirmed by identifying an underlying
cardiac dysfunction in the UK study, while in our cohort
diagnosis was based on criteria in the general practice
setting [30]. Such differences in survival rates betweenpatients with definite versus possible CHF were recently
reported in a general practice population [7]. The 5-year
survival rate in our study is somewhat lower than in The
Rotterdam Study (45% versus 59%), which may be related
to the fact that we studied incident cases, while The
Rotterdam study included prevalent cases [4].
Increasing age is a known risk factor for mortality both in
the community and in patients with CHF [31,32]. Sex related
differences in mortality have been reported, but results are
contradictory. Higher mortality rates are reported for male
compared to female patients with CHF [4,5,7,32]. Others
have found no sex related effect [6,30,33] or report complex
interactions between age and sex [3]. Our results show that
male sex was related to increased mortality among patients
aged 75 years only, while sex was not a significant risk
factor among older patients (76 years). A recent commun-
ity-based study in the UK also reported better survival
among younger female patients, but not among older CHF
patients [7]. The better survival among female patients (aged
75 years) is in contrast with reports of worse quality of life
and more comorbidities in female compared to male CHF
patients [34]. Sex related differences in aetiology and
increased diastolic heart failure among females are suggested
as explanations for this difference in mortality [35].
In conclusion, mortality rates for CHF are high, especially
in the first year, but continue to be high in the long-term.
Mortality is even higher among older patients, and among
patients aged 75 year mortality is higher among males
compared to females. Overall, long-term survival rates
among patients with CHF from a community-based setting
are even worse than the known survival rates from clinical
trials. There is a need for studies that describe the care of
patients with CHF in the community, including the type of
care, the provider, the quality of care and the outcome.Acknowledgements
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